Questions to Ask About Esophageal Cancer Treatment

This page is for people with esophageal cancer and those helping them. It walks through the treatment decisions in order, with questions to ask your care team at each step.

Esophageal cancer treatment is not one choice. It is a sequence, and each step narrows what comes next. Knowing which decision is on the table today makes it far easier to ask a useful question.

Two numbers frame the conversation. Across all stages, SEER (NCI's cancer statistics program) puts 5-year relative survival at 22.2% for 2016 through 2022. About 19% of people are diagnosed while the cancer is still confined to the primary site, and in that group the figure is 48.6%. Stage is the largest single lever. That is why the staging work-up gets so much attention up front.

Some very early tumors can be removed through a scope. So can severe dysplasia (badly abnormal cells that are not yet cancer) in Barrett esophagus, a condition where acid reflux changes the lining of the lower esophagus. That avoids taking out the esophagus. NCI adds a caution. People with severe dysplasia in the lower Barrett lining often already have in-situ or invasive cancer inside that area. After it is removed, though, outcomes are usually excellent.

Worth asking:

• How deep has the tumor grown, and which test established that?
• Am I a candidate for endoscopic resection (removal through a scope)?
• If the pathology after endoscopic removal shows deeper invasion, what happens next?

This is where the evidence has moved recently, and where the two main options genuinely compete.

Chemoradiation first, the CROSS approach. The CROSS trial enrolled 366 people with removable esophageal or junctional cancer. Half had surgery alone. Half had weekly carboplatin plus paclitaxel by vein, at amounts the protocol calculated for each person. Radiation was 41.4 Gy (gray, the unit of radiation dose) in 23 fractions, or daily treatments, over five weeks. Surgery followed. At a median follow-up of 84 months, median survival rose from 24 months to 48.6 months. The effect differed by cell type. For squamous cell cancers it was 81.6 versus 21.1 months. For adenocarcinomas it was 43.2 versus 27.1 months. Local recurrence fell from 34% to 14%.

Chemotherapy before and after, the FLOT approach. FLOT is four drugs on a 2-week cycle. They are docetaxel, oxaliplatin, leucovorin, and fluorouracil, the last running continuously over 24 hours. Every amount is calculated by the chemotherapy pharmacy from your body size. Four cycles run before surgery and four after. In a trial of 716 patients with adenocarcinoma, FLOT gave a median survival of 50 months. The older ECF/ECX regimen gave 35 months.

The head-to-head trial. ESOPEC compared the two directly. It enrolled 438 people with removable esophageal adenocarcinoma. At a median follow-up of 55 months, the 3-year survival rate was 57.4% with FLOT. It was 50.7% with CROSS chemoradiation. Median survival was 66 months versus 37 months.

One caveat belongs with that result, and NCI states it. Patients in the ESOPEC chemoradiation arm did not get a year of nivolumab afterward. In CheckMate 577, a year of nivolumab after surgery helped people who still had cancer in the removed tissue. So this matters for how the comparison reads.

Worth asking:

• Is my tumor adenocarcinoma or squamous cell, and does that change which approach you recommend?
• Would you offer FLOT or CROSS chemoradiation in my case, and why that one?
• How many of the planned cycles do people usually complete after surgery?

If the removed tissue still shows cancer after chemoradiation, one specific option applies.

CheckMate 577 enrolled 794 adults. All had stage II or III disease removed with clear margins. All had chemoradiation first, and all still had cancer left in the specimen. Half got nivolumab by vein every 2 weeks for 16 weeks, then a larger amount every 4 weeks, for up to a year. Half got placebo.

Median disease-free survival was 22.4 months with nivolumab and 11.0 months with placebo. By cell type, it was 19.4 versus 11.1 months for adenocarcinoma and 29.7 versus 11.0 months for squamous cell carcinoma.

There is a limit on that finding. Overall survival data from CheckMate 577 have not been published. Serious side effects of any grade hit 30% of each group. But severe side effects tied to the drug were more common with nivolumab: 13% versus 6%. And 9% stopped treatment because of them, against 3% on placebo.

Worth asking:

• Did my surgical specimen show a complete response, or residual cancer?
• Am I eligible for a year of adjuvant (after-surgery) nivolumab, and what would the schedule look like?
• What side effects would make us stop it?

For advanced squamous cell cancer, CheckMate 648 enrolled 970 adults with no prior treatment. The results split by PD-L1, a marker measured on the tumor. Among those at 1% or more, median survival was 15.4 months with nivolumab plus fluorouracil and cisplatin. It was 13.7 months with nivolumab plus ipilimumab, and 9.1 months with chemotherapy alone. Among tumors under 1%, adding nivolumab did not change survival much.

For adenocarcinoma, FDA acted in 2021. It approved nivolumab with fluoropyrimidine- and platinum-based chemotherapy. The approval covers advanced or spread gastric, gastroesophageal junction, and esophageal adenocarcinoma.

That is why the PD-L1 result is not a formality. Ask what your number is, and what it changes. Our page on biomarker testing explains how these results are produced.

About the surgery itself. An esophagectomy is a major operation. Ask how many the surgeon and the hospital do each year. Ask what their leak rate is at the join.

About eating. Ask who on the team handles nutrition and swallowing, whether a feeding tube is likely during chemoradiation, and whether a stent would complicate a later operation.

About sequencing. Ask which decisions must be made this week and which can wait for a pending result.

About a second look. A tumor board review or a second opinion helps most in three cases. When the cell type or stage sits at a boundary. When major surgery is on the table. When biomarker results are incomplete. Ask whether trial eligibility depends on starting something now, or not starting it. See clinical trial versus standard treatment.

For the disease itself and how it is described, start with esophageal cancer and cancer staging.

• National Cancer Institute, Esophageal Cancer Treatment, accessed August 6, 2026
• National Cancer Institute, Esophageal Cancer Treatment PDQ, health professional version, updated March 21, 2025; accessed August 13, 2026
• National Cancer Institute, SEER Cancer Stat Facts: Esophageal Cancer, accessed August 13, 2026